Crossref
Satralizumab, an IL-6 Receptor Blocker, Shows Promise in the Treatment of Thyroid Eye Disease
Clinical Thyroidology® · 01.11.2026 · 38 (11) · 374-376
DOI: 10.1177/23299711261506080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Thyroidology®, online erschienen am 16.11.2026. Verfasst von Johnson Thomas. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Thomas, J. (2026). Satralizumab, an IL-6 Receptor Blocker, Shows Promise in the Treatment of Thyroid Eye Disease. Clinical Thyroidology®, 38(11), 374-376. https://doi.org/10.1177/23299711261506080
Vancouver
Thomas J. Satralizumab, an IL-6 Receptor Blocker, Shows Promise in the Treatment of Thyroid Eye Disease. Clinical Thyroidology®. 2026;38(11):374-376. doi:10.1177/23299711261506080
BibTeX
@article{Thomas2026,
author = {Thomas, Johnson},
title = {Satralizumab, an IL-6 Receptor Blocker, Shows Promise in the Treatment of Thyroid Eye Disease},
journal = {Clinical Thyroidology®},
year = {2026},
volume = {38},
number = {11},
pages = {374--376},
doi = {10.1177/23299711261506080}
}
EUVIMED